Tokyo and his postdoctoral research at Brown University and the Unversity of Wisconsin. The work in his laboratory concerns the cellular and molecular biology of chemically induced multistage carcinogenesis in rodents. Current investigations center on understanding the mechanisms for the paradoxical effects of phenobarbital, a classical hepatopromoter, on diethylnitrosamine-initiated mouse hepatocarcinogenesis. Another focus of research is on the genetic factors that can play an important role in determining an individual's risk for developing tumors. Inbred strains of mice, which differ markedly in sensitivity to induction of liver or lung neoplasms, are used as models tor elucidating the action of tumor susceptibility genes. the initial goal is to determine the molecular identities of those genes using a &dquo;reverse genetic&dquo; approach.
PHENOBARBITAL AND 2-STAGE HEPATOCARCINOGENESIS The 2-stage concept of carcinogenesis originally proposed for development of skin tumors in mice (5) is now widely accepted among cancer investigators. In the first stage, initiation, normal cells become initiated or preneoplastic due to irreversible genetic events induced by initiators (6, 37, 47) . Because many carcinogens are genotoxic, initiation is believed to be caused by gene mutations. During the second stage, promotion, the initiated cells are provoked to grow and give rise to tumors. Fac-tors that positively modulate the promotion stage are called promoters and are generally nongenotoxic, exerting their effects through epigenetic mechanisms. Promotion may be reversible, and tumors may regress after withdrawal of promoters.
Initiating and promoting effects can be quantified (37, 47) . Initiation means de novo induction of preneoplastic cells, each of which has potential for clonal growth. Thus, there must be a positive correlation between the initiating stimulus and the total number of initiated lesions. The initiated lesions here include both preneoplasia and neoplasia. Promotion is the stage when the initiated cells replicate to form focal lesions. Therefore, promoting effects are reflected in an increase in mean size of the initiated lesions.
In 1971, Peraino et al (44) discovered that phenobarbital (PB), a classical antiseizure medication for human epileptics, exhibits an enhancing effect on development of hepatocellular tumors in rats briefly pretreated with a potent hepatocarcinogen, 2-acetylaminofluorene . Whereas 2-AAF alone is carcinogenic with unequivocal genotoxicity, PB itself has been shown to be nongenotoxic and to lack carcinogenicity, at least in shortor medium-term in vivo assays in rats (37, 47) .
Thus, Peraino et al's report provided the first evidence that the 2-stage concept of carcinogenesis is also applicable to hepatocarcinogenesis, with 2-AAF as an initiator and PB as a promoter. Subsequently, a number of nongenotoxic chemicals have ben identified that possess hepatopromoting effects in rats pretreated with various mutagenic initiators, including the very potent diethylnitrosamine (DEN) (37) .
Although hepatopromoters act through enhancing proliferation (36) or inhibiting apoptosis (53) in initiated hepatocytes, the molecular mechanisms underlying such biologic actions are not well understood. According to recent studies by Mills and coworkers (36) , however, PB causes elevated production of transforming growth factor(TGF)-r3 in the normal rat liver. In contrast, PB-promoted rat liver tumors express decreased levels of TGF-(3 and its receptors relative to surrounding nonneoplastic liver tissue. Furthermore, those tumors are deficient in the mannose 6-phosphate/insulinlike growth factor 2 receptor, which is required for activation of the extracellular latent complex of TGF-r3 (36) . Because TGF-r3 is an inhibitor of epithelial proliferation and an inducer of apoptosis, an attractive hypothesis is that PB selectively promotes initiated hepatocytes with altered phenotypes, conferring insensitivity to the negative effects of TGF-r3 (36, 53) . When Peraino et al (44) discovered the promoting function of PB, its opposite effect on hepatocarcinogenesis was also noted. Concomitant administration of PB and 2-AAF resulted in marked inhibition of 2-AAF-initiated hepatocellular tumors in rats. Because PB markedly induces hepatic microsomal enzymes, which play an important role in detoxication of harmful chemicals including carcinogens, this inhibitory effect is attributable to elevation of enzyme activity metabolising 2-AAF to harmless water-soluble species that are easily excreted (37) . Consistently, PB inhibits rat hepatocarcinogenesis when concomitantly administered with most initiating chemicals (37), including DEN (2) . PB may also act as a hepatopromoter for mouse hepatocarcinogenesis, as initially demonstrated in C3H mice (45) . These mice frequently develop spontaneous hepatocellular tumors because of their genetic background (14, 19, 24, 27) . PB significantly promotes the development of hepatocellular tumors despite no pretreatment with an initiator (45) . This effect can be explained by the assumption that PB promotes growth of spontaneously initiated hepatocytes in C3H mice (34, 56) . However, biologic effects of PB in mice seem to be more complex than those in rats. For example, PB strongly inhibits mouse hepatocarcinogenesis under certain conditions even if administered well after initiation (11, 41) .
Under those conditions, carcinogen detoxication cannot be involved in the inhibition of tumor development.
This review article is mainly focused on the paradoxical effects of PB on mouse hepatocarcinogenesis. Male mice are preferentially used for studies of hepatocarcinogenesis because they are far more susceptible to these effects than females because of the proven promoting effects of androgens (38) . Thus, unless specified, only results with male mice are considered here.
PROMOTION AND INHIBITION BY PB OF B6C3F, MOUSE

HEPATOCARCINOGENESIS INITIATED WITH DEN
The F1 progeny from female C57BL/6 and male C3H/ He mice, designated B6C3Fj, are standard animals for experimental safety assessment (12) . Although the parental C57BL/6 and C3H/He mice are respectively resistant and highly sensitive to both spontaneous and chemically induced hepatocarcinogenesis, B6C3F, mice are nearly as sensitive as the C3H/He mice because of the semidominance of the C3H/He phenotype (13, 14, 24) .
DEN is the most commonly used initiating agent for the mouse liver because of its high initiating activity (55) . Although DEN is usually refered to as an initiator, it is itself sufficient to induce hepatocellular neoplasms. I and others have proposed that tumors induced by DEN alone result from initiation with DEN and promotion with endogenous factors, eg, growth factors and oncogene products (24) . There are at least 3 established protocols that are used for initiation of mouse livers with DEN. In protocol 1 (Figure lA ), mice are simply injected IP with a large hepatonecrogenic dose of DEN (80-90 f.1g/g body weight) at 4 or 5 weeks of age (10, 57) . Because mice are usually weaned at around 21 days of age, the injection of DEN for protocol 1 is performed 1 or 2 weeks after weaning. Protocol 2 (Figure 1 A) is a modified version of the Pitot protocol for rat hepatocarcinogenesis (47) . Mice at 5 or 6 weeks of age initially undergo a two-thirds partial hepatectomy. Thirty-six hours after the operation, when most regenerating hepatocytes enter the pre-S or the S phase of the cell cycle, the mice are injected IP with a moderate nonnecrogenic amount of DEN (20 f.1g/ g body weight) (23, 30) . This protocol is designed to increase the initiation efficiency by virtue of regeneration of the target cells. Protocols 1 and 2 are comparable in efficiency of tumor production, and 5-10 hepatocellular tumors develop in each B6C3F; ¡ mouse after 1 year. These 2 protocols are referred to as postweaning protocols because weaned mice are injected with DEN ( Figure  1 A). However, in protocol 3 (Figure 1 B ) , originally described by Vesselinovitch and Mihailovich (55) , suckling mice are treated with a low dose of DEN (5 f.1g/g body weight) between 12 and 15 days of age. This protocol is more efficient because individual B6C3F, mice develep more than 60 hepatocellular tumors by the age of 36 weeks. Thus, protocol 3 is called the preweaning protocol because mice are injected with DEN about 1 week before weaning ( Figure 1B ). When B6C3F, mice are subjected to initiation with DEN following either of the postweaning protocols and then chronically treated with 500 ppm of PB in the diet or drinking water, mean multiplicity of hepatocellular tu-FIGURE 1.-Representative postweaning (A) and preweaning (B) protocols for DEN-initiation in the mouse liver. Regimens for PB treatment are also shown. In all cases, DEN is given IP The two-thirds partial hepatectomy for protocol 2 is performed 36 hours prior to the injection of DEN. Visible tumors on the liver surfaces larger than 1 mm in diameter were enumerated at sacrifice for determination of the mean numbers of gross liver tumors in male B6C3F, mice. The approximate mean numbers indicated are from G.-H. Lee (unpublished observations). mors in these mice is significantly increased by 4-5-fold relative to the appropriate controls treated with DEN alone (Figure lA) (23, 57) . This promoting effect is similar to that observed in rats. B6C3Ft mice spontaneously develop hepatocellular tumors, although the incidence is less than that for the parental C3H/He strain. PB also has been demonstrated to promote spontaneous hepatocarcinogenesis in B6C3F, mice as in C3H/He mice (3) . In these cases, PB clearly behaves as a promoter.
However, as first noted by Diwan et al (11) , DEN ini-tiation of B6C3F, mice with the preweaning protocol followed by chronic PB treatment after weaning results in a more than 90% reduction of tumor multiplicity relative to the DEN alone controls ( Figure 1B ). This paradoxical result was later confirmed by Pereira et al (46) . Because PB application was after completion of the initiation, the inhibitory effect could not be attributed to its induction of hepatic detoxicating enzymes. To explain this apparent paradox, Diwan et al pointed to the testicular atrophy that can be caused by this agent in sexually immature animals; in their experiment, application of PB was started at the age of 4 weeks when the mice were already weaned but were still undergoing sexual development. Androgens mainly produced in testes are strong hepatopromoters in mice (38) . Diwan et al therefore proposed that a reduction in serum androgens due to testicular dysfunction might have caused the inhibition of hepatocarcinogenesis (11) .
Although this hypothesis appears plausible, direct proof has yet to be obtained. In 1 study, the inhibitory effect of PB on B6C3Fi mouse hepatocarcinogenesis remained intact when the start of the PB administration was delayed to 12 weeks of age (22) . An alternative hypothesis has recently been proposed to resolve the apparent paradoxical effect of PB (32) . Before presenting this hypothesis, I present a discussion of the qualitative heterogeneity of DEN-initiated hepatocellular lesions.
HETEROGENEITY OF DEN-INITIATED LESIONS IN SENSITIVITY TO PB PROMOTION
A number of studies have provided evidence that initiated lesions constitute a qualitatively heterogeneous population. In particular, initiated lesions emerging under initiation-promotion conditions may be largely distinct from those induced by an initiator alone (49) .
Initiated murine hepatocellular lesions can be divided into 3 histopathologic categories: preneoplastic hepatocellular foci, hepatocellular adenomas, and carcinomas. By definition, only adenomas and carcinomas are neoplastic in nature and thus are called tumors. Each preneoplastic focus is a focal proliferative lesion usually smaller than a hepatic lobule. It originates from clonal growth of a single initiated hepatocyte. Preneoplastic foci are potentially promotable to hepatocellular adenomas, each of which is typically larger than a hepatic lobule. According to the diagnostic criteria, hepatocellular carcinomas, thought to develop through malignant progression of hepatocellular adenomas, are infrequently encountered within standard observation times (usually less than 10% of all tumors). Here, I refer to initiated lesions (or simply lesions) as a combined population of preneoplastic foci, adenomas, and carcinomas. As for chemically initiated mouse livers, 2 major cytologic subtypes of initiated hepatocellular lesions, ie, basophilic and eosinophilic, have been described (18) . The first type features enhanced cytoplasmic basophilia and usually smaller cells relative to normal hepatocytes ( Figure 2B ). Thus, hepatocytes of eosinophilic lesions have a mature morphology. Both types of lesions may give rise to hepatocellular adenomas and carcinomas.
When B6C3Fi mice were initiated with DEN according to a postweaning protocol with no further treatment performed, 86% of gross hepatocellular tumors larger than 1 mm in diameter were basophilic ( Figure 3A ) (23, 57) . In contrast, 88% of the gross tumors with the postweaning protocol promoted with PB were eosinophilic ( Figure 3A ) (23, 57) . These results indicate that PB selectively promotes eosinophilic initiated lesions or converts basophilic initiated lesions to eosinophilic lesions. However, the latter possibility is unlikely; Pedrick et al (43) reported that the PB-promoted eosinophilic tumor cells exhibit a phenotype distinct from that of their basophilic counterparts, even in tissue culture. In addition, basophilic tumors often contain activated H-ras oncogenes, which the eosinophilic tumors lack (17, 35, 50, Recently, I found that virtually all basophilic lesions in B6C3F, mice express Bcl-2 protein, an antiapoptotic oncogene product irrespective of PB promotion, whereas normal hepatocytes and eosinophilic lesions are Bcl-2 negative (23) . Even the very small preneoplastic hepatocellular foci composed of basophilic cells expressed Bcl-2, indicating that its increase is an early event in hepatocarcinogenesis. It is not known whether the Bcl-2 proteins expressed in basophilic tumors contribute to tumorigenesis by inhibiting apoptosis. Because normal bile ductular cells are also positive for Bcl-2, the Bcl-2 expression in the basophilic tumors could result from a metaplastic shift to bile ductular phenotype, a phenomenon often observed in hepatocellular neoplasms (23) . However, the eosinophilic lesions developing with or without PB promotion are invariably Bcl-2 negative (23) . Similarly, Christensen et al (7) reported that all spontaneous liver tumors in B6C3F, mice overexpressed Bcl-2 proteins, but only 20% of those developing with PB alone were positive, indicating that PB may selectively promote Bcl-2-negative lesions irrespective of the nature of the initiation stimulus. Also, the PB-promoted Bcl-2-negative tumors overexpressed another antiapoptotic protein, Bel-XL (7) . The roles of these antiapoptotic proteins in hepatocarcinogenesis await future investigations. Another event differentially involved in the 2 histologic types of lesions is selective expression of TGF-a, an epithelial growth factor, in eosinophilic lesions of female B6C3F, mice (39) . TGF-a can be an endogenous hepatopromoter acting through an autocrine pathway in TGFa transgenic mice (28) . Thus, development of eosinophilic lesions might depend on expression of TGF-a. It is unknown whether PB augments TGF-cx expression in eosinophilic lesions. However, it is a plausible mechanism for selective promotion of eosinophilic lesions by PB.
REANALYSIS OF THE PARADOXICAL INHIBITORY EFFECT OF PB ON MOUSE HEPATOCARCINOGENESIS CONSIDERING HETEROGENEITY OF INITIATED LESIONS
Although Diwan et al (11) proposed that the inhibitory effect of PB on B6C3F, mouse hepatocarcinogenesis initiated with DEN by the preweaning protocol could be due to testicular atrophy caused by early application of PB, I hypothesized the alternative possibility that initiated lesions induced by the preweaning protocol may be qualitatively distinct from the PB-promotable lesions induced by postweaning protocols. Because PB selectively promotes Bcl-2-negative eosinophilic lesions, I speculated that B6C3F, mice given the preweaning initiation harbor few eosinophilic lesions relative to those subjected to the postweaning protocol. My research group thus reanalyzed the inhibitory effect of PB on hepatocarcinogenesis in B6C3F, mice subjected to the preweaning protocol, taking into account the qualitative heterogeneity of initiated lesions (32) . B6C3F~ mice were DEN initiated with the preweaning protocol. Starting at 6 weeks of age, mice of the first group, PB ( + ), were treated with 500 ppm of PB in the diet and those of the second group, PB(-), were continued on the normal diet. At 24 weeks of age, half of the PB(+) animals were returned to the normal diet [PB(+/-) group] and half of the PB(-) animals were switched to the PB diet [PB(-/+) group]. All mice were sacrificed at 36 weeks of age and examined for the development of gross hepatocellular tumors. As expected, the mean tumor multiplicity for the PB(+) group was only 7% of that for the PB(-) group (Table 1) . Furthermore, the multiplicity in the PB(-/+) animals was 44% of that of PB(-) animals ( Table 1 ). Because PB treatment of PB(-/+) animals was started after their sexual maturation, the inhibitory effect of PB was strongly suggested not to be attributable to failed maturation of immature testes. The effect was also found to be reversible, because the mean tumor multiplicity for the PB(+/-) group was 7 times larger than that for the PB(+) animals (Table 1) . Gross hepatocellular tumors, larger than 1 mm in diameter, induced by the preweaning protocol were histopathologically examined. In clear contrast to the situation with the postweaning protocols, all tumors encountered were of basophilic type, independent of the PB treatment ( Figure 3B ). Most tumors were diagnosed as hepatocellular adenomas. Frequencies of hepatocellular carcinomas, including those arising in adenomas, were less than 2% irrespective of the group. The histologic analysis was then extended to all classes of initiated lesions, ie, preneoplastic hepatocellular foci, hepatocellular adenomas, and carcinomas. To assure reproducible detection of the initiated lesions in hematoxilin and eosin (H&E)-stained sections, only those lesions larger than 160 f.1m in transection diameter were investigated. In the PB(-) group, all initiated lesions encountered were of the basophilic type. Furthermore, over 96% of the initiated lesions were basophilic in the PB(+) group. Thus, all classes of initiated lesions were predominantly basophilic after initiation with the preweaning protocol, even with the PB treatment, confirming that this protocol preferentially initiates basophilic lesions. Although the percentage of eosinophilic initiated lesions was at most 4%, they reached histologically detectable sizes in a PB-dependent manner. Therefore, PB promotion of eosinophilic lesions did occur even under such conditions. Immunohistochemical and western blot analyses confirmed the basophilic and eosinophilic lesions to be Bcl-2 positive and Bcl-2 negative, respectively.
A 3-dimensional analysis of number and size (16) was performed with all kinds of initiated lesions (32) . Again, only those larger than 160 fJLm in transection diameter were studied. The mean volume of initiated lesions in the PB(-) animals was The proliferating nuclear antigen (PCNA) labeling index (%), a surrogate of proliferating cells in early Gl and S phases of the cell cycle, was immunohistochemically assessed for 2 or 3 of the largest basophilic hepatocellular adenomas of each animal (32) . Apoptotic hepatocytes were counted in H&E-stained sections to determine apoptotic indices (%) of the adenomas (32) . Carcinomas and eosinophilic tumors were excluded in these studies because of their limited numbers. Hepatocellular adenomas developing in the PB(+) and PB(-/+) animals had 2-3 times lower mean PCNA labeling indices than those in the PB(-) and PB(+/-) animals ( Table 2) . Conversely, the PCNA indices of normal livers for the PB(+) and PB(-/+) groups were 2.5-3 times higher than those for the PB(-) and PB(+/-) groups ( Table 2 ). The mean apoptotic indices for tumors were generally very low, and there were no intergroup differences ( Table 2 ). The apoptotic values for tumors, however, tended to be higher than the values for normal livers (Table 2 ). Consequently, the inhibitory effects of PB on development of the basophilic tumors may be primarily due to suppression of tumor cell proliferation but not to induction of apoptosis. The results of these studies provided strong evidence that age-dependent initiation, together with the differential responses of Bcl-2-positive basophilic lesions and Bcl-2-negative eosinophilic lesions, may be responsible for the apparently contradictory results of PB treatment in B6C3Fj mice (Figure 4 ). Whereas basophilic lesions possess intrinsically high autonomous growth ability, this ability is suppressed by PB treatment. The autonomous growth ability of eosinophilic lesions is poor, but the growth of these lesions is remarkably promoted by PB treatment.
The reason for age-dependent initiation of basophilic and eosinophilic lesions is not known. However, it might be related to the maturity of target hepatocytes. Although these cells in preweaning animals are actively proliferating, this proliferation slows markedly after weaning. In this sense, preweaning hepatocytes may be considered phenotypically immature. When such hepatocytes are initiated, their maturation program might freeze, resulting in basophilic lesions with immature morphology and autonomous growth ability. However, when mature hepatocytes of weaned mice are initiated, eosinophilic lesions with mature morphology and limited autonomous growth ability might preferentially occur.
INFLUENCE OF GENETIC BACKGROUND ON DEN-INITIATED AND PB-PROMOTED HEPATOCARCINOGENESIS
Inbred mouse strains differ markedly in susceptibility to spontaneous and chemically induced hepatocarcinogenesis, indicating a major influence of genetic control (14, 24) . Although the susceptible B6C3F1 mice are most commonly used for experimental safety assessment, data for major inbred strains are also available. Drinkwater and coworkers (14) treated various inbred strains of mice with the preweaning protocol of DEN injection and classified them into sensitive and resistant according to the mean liver tumor multiplicity (14) . The C3H/He, CBA, DBA/2 strains were highly sensitive, but the C57BL/6, BALB/c, and A strains were resistant. Some of the genes responsible for these phenotypic variations have been chromosomally mapped by linkage analysis (4, 25) . Among those, the Hcs (hepatocarcinogen sensitivity) genes, which determine the phenotypic difference between C3H/He and C57BL/6 mice, are best characterized (4, 13) . They are thought to be expressed in hepatocytes (29) and seem to control susceptibility to hepatocellular tumors by affecting cellular proliferation (14, 24) .
Generally, susceptibility of a mouse strain to hepatocarcinogenesis with the preweaning protocol of DEN application correlates well with spontaneous tumor development or the results of postweaning protocols (10, 19, 30) , with the exception of DBA/2 mice. These mice are highly susceptible with the preweaning protocol but are resistant in terms of spontaneous tumors (54) and postweaning protocols (10, 14, 24) . The biology and genetics of this unique susceptibility have been studied in detail (25, 26) .
Mouse strains exhibit specific susceptibilities to PB as FIGURE 4.-A) Characteristics of basophilic and eosinophilic initiated lesions (ie, preneoplastic hepatocellular foci and hepatocellular adenomas) induced by DEN and their responses to PB treatment. Hepatocellular carcinomas are not included because their occurrence is infrequent. B) Proposed mechanisms for the paradoxical effects of PB on male B6C3F, mouse hepatocarcinogenesis initiated with DEN. The preneoplastic foci at the time of initiation stand for single initiated hepatocytes. well as DEN. When mice are initiated with an postweaning protocol and then administered PB, tumor development is promoted in C3H/He, DBA/2, and BALB/c mice, as in B6C3F1 mice, but not in C57BL/6 mice (10, 30). Diwan et al (10) compared serum PB concentrations of PB-treated mice and found that serum levels in DBA/2 mice were significantly higher than those in C57BL/6 mice. DBA/2 mice appeared to be unable to eliminate PB because of low hepatic microsomal enzyme activities, whereas C57BL/6 mice may detoxify PB with efficient induction of those enzymes (10) . Thus, the PB-responsive phenotype of DBA/2 mice might be caused by the lower activity of the enzyme system in these mice than in C57BL/6 mice (10). However, this explanation is not applicable for the PB sensitivity of C3H/He mice, because the serum PB level was not different between C3H/He and C57BL/6 mice. Initiated hepatocytes in these 2 strains may be qualitatively different in terms of sensitiv-ity to PB promotion (10) . Because eosinophilic and basophilic tumors in B6C3F1 mice are respectively responsive and nonresponsive to PB promotion, histologic characterization of the tumors developing in C3H/He and C57BL/6 mice may provide a clue to understanding strain differences in PB promotion. These differences also exist when mice are initiated with DEN in the preweaning protocol. Although liver tumor development in B6C3F1 and A mice treated in the preweaning stage with DEN is inhibited by PB (11, 41) , in BALB/c and C3H/He mice these lesions are promoted under the same conditions (46, 58, 60) . If our findings for dissecting the paradoxical effects of PB on B6C3F1 mice are generally applicable, BALB/c and C3H/He mice should develop precusors for eosinophilic tumors even with the preweaning protocol.
This hypothesis is currently being tested.
Given that B6C3Fi mice are derived from C57BL/6 and C3H/He parents, C57BL/6 mice should carry genes that dominantly suppress initiation of PB-promotable lesions with the preweaning protocol. I have tentatively named these genes Pbi (phenobarbital inhibition) genes. According to the hypothesis, the C57BL/6 alleles of Pbi genes should dominantly inhibit initiation of eosinophilic lesions in preweaning mice. In addition, Weghorst and Klaunig (59) reported that, unlike in male B6C3F, mice, PB promoted liver tumors in female B6C3F1 mice initiated with the preweaning protocol for DEN. This finding suggests that the dominant Pbi phenotype is preferentially expressed in the male environment. Analysis of the Pbi genes in terms of their number and chromosomal positions is also now in progress.
BIOLOGICAL EFFECTS OF PB IN CULTURE
Both human and rodent hepatocytes possess very limited growth ability in vitro, even with potent growth factors, and usually die within 2 weeks after their transfer into culture. Because PB has been regarded as a classical hepatopromoter in vivo, there have been considerable efforts to prove direct effects on primary hepatocytic growth utilizing tissue culture models. In fact, multiple reports that PB can promote in vitro proliferation of primary rat hepatocytes have been published (1, 15, 52) . However, the growth-promoting effect of PB on primary normal hepatocytes is transient and does not lead to permanent growth. This finding is consistent with the in vivo phenomenon that application of PB to rats results in initial promotion of growth of normal hepatocytes, but this growth rate returns to the baseline value within several days (44) . In contrast, when preneoplastic rat hepatocytes chemically initiated in vivo are transfered to culture and maintained with 1.5-2 mM of PB, they are promoted to grow and form colonies that eventually give rise to clonal hepatocytic cell lines (21) . Some of the cell lines are tumorigenic and produce hepatocellular carcinomas after back transplantation into syngeneic rats or nude mice (21) . Untreated C3H/He mice without liver tumors should carry spontaneously arising preneoplastic hepatocytes because they frequently develop spontaneous hepatocellular tumors. When hepatocytes were isolated from untreated C3H/He mice at 6-8 weeks of age, when these animals are grossly free of liver tumors, multiple continuously growing hepatocytic colonies appeared among dying normal hepatocytes. These colonies then became immortalized after cloning (34) . Addition of 1.5 mM PB to the medium resulted in marked growth promotion of the hepatocytic colonies (34) . The clonal hepatocytic lines transformed either spontaneously or by transfection of an activated H-ras oncogne produced hepatocellular carcinomas in nude mice (33) . Because hepatocytes from C57BL/6 mice with a low incidence of spontaneous hepatocellular tumors produced almost no such hepatocytic colonies, it can be hypothesized that the colony-forming hepatocytes from C3HIHe mice represent spontaneously initiated hepatocytes that respond to PB promotion both in vivo and in vitro (34) .
Although these results suggests that PB can also behave as a hepatopromoter in culture and that its promoting action directly affects preneoplastic hepatocytes, more complex effects of PB in vitro have been demonstrated, particularly in terms of its influence on hepatocyte apoptosis. Using a conditional hepatocellular transformation system in vitro (31), Osanai et al (42) recently found that PB at 1 mM or higher concentrations induces apoptosis in mouse hepatocytes, cooperating with overexpression of the c-myc oncogene. This apoptosis was accompanied by increase in the apoptotic protein, Bax.
Because introduction of an activated H-ras oncogene resulted in de novo induction of the Bax antagonist, Bcl-2, and complete inhibition of apoptosis, the hepatocyte apoptosis caused by PB and c-myc overexpression may depend on Bax proteins. The relevance of this phenomenon to in vivo hepatocarcinogenesis is still unknown. However, the data indicate that biologic effects of PB are complex in vitro as well as in vivo.
CONCLUSIONS
Although PB has been considered a representative promoter for hepatocarcinogenesis, its effects are quite complicated and even paradoxical in the mouse. Recent work indicates that anomalous effects of PB in B6C3F) mice can be resolved by considering qualitative heterogeneity of initiated lesions and their differential responses to promoter stimulus (23, 32) . The classical 2-stage concept of carcinogenesis regarding DEN initiation and PB promotion of B6C3Fj mouse livers applies only to eosinophilic initiated lesions; at least some basophilic lesions were inhibited by PB. These 2 types of lesions are distinct not only in histology but also in molecular characteristics. Ward et al (57) reported that di(2-ethylhexyl)phthalate selectively promotes basophilic rather than eosinophilic lesions after initiation with the postweaning protocol. Thus, the outcomes of promotion depend on both histologic features of initiated lesions and the promoter type. I propose that the known hepatopromoters for mice should be re-evaluated in view of such qualitative diversity in preneoplastic lesions.
Qualitative heterogeneity of initiated lesions has also been noted for other experimental models of carcinogenesis. Preneoplastic rat hepatocytes induced by x-ray irradiation do not to respond to PB promotion (20) , in contrast to their chemical carcinogen-initiated counterparts (44) . In addition, rat liver tumors promoted by peroxisome proliferators are different in enzyme profile from those promoted by PB (48) . Likewise, mouse skin papillomas induced by initiation with dimethylbenzanthracene and promotion with tetradecanoylphorbol acetate may differ from those induced by dimethylbenzanthracene alone (49) . For rat mammary carcinogenesis, the frequency of activated H-ras oncogenes in tumors initiated with methylnitrosourea was reduced by increasing the doses of the initiator or by promotion with prolactin (62) . This finding indicates that tumors without an H-ras mutation may have less autonomous growth ability, with development more dependent on initiator dose and promotion than in those tumors with such mutations. Thus, heterogeneity of initiated lesions seems to be a universal feature of carcinogenesis.
The hepatopromoting effect of PB also depends on the genetic background of the mice. Similar genetic variation in sensitivity to a skin promoter, tetradecanoylphorbol acetate, has been reported with inbred mouse strains (40) . In some cases, such differences can be simply explained by genetic variation in activity of detoxifying enzymes acting on promoters. However, in other cases, this explanation is not applicable. One reasonable hypothesis is that genetic background determines a specific ratio of promotable vs unpromotable initiated lesions. This hypothesis can be readily tested with DEN-initiated and PBpromoted mouse hepatocarcinogenesis, because PB-promotable and -unpromotable lesions can be distinguished by histologic observation.
Epidemiologic surveys of human epileptics chronically treated with PB indicated no significant increase in risk of liver tumors (8, 9) . This finding is not necessarily surprising because hepatic metabolic states involved in inactivation of rodent hepatopromoters are known to be considerably different among species (37) . In addition, experimentally induced initiated lesions in rodents may not be simply regarded as counterparts of those in humans because most hepatocellular carcinomas that develop in humans are associated with chronic infection by hepatitis B or C virus rather than exposure to chemical carcinogens (14, 23, 37) . However, considering that the effects of PB largely depend on the nature of initiation and the genetic background of the population, epidemiologic findings require replication with various human populations before a final conclusion can be reached. PB may conditionally act as either a promoter or an inhibitor of hepatocarcinogenesis in humans as in mice. B6C3F1 mice are the standard test animals for detection of carcinogens (12) . Thus, the paradoxical effects of PB raise a practical issue when extrapolating from laboratory animal data to assessment of human risk. Clearly, further studies are needed to elucidate the mechanisms of mouse hepatocarcinogenesis and their relevance to the human situation.
ACKNOWLEDGMENTS I gratefully acknowledge the contributions of Dr Makoto Osanai and Dr Takao Ooasa to the original studies cited here. This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture, Japan.
